Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis

Fig. 4

OS in IDH-mutant AML patients treated with IDH inhibitors. A 2-year OS rate in newly diagnosed AML patients treated with IDH inhibitors; B 2-year OS rate in newly diagnosed AML patients treated with IDH inhibitors in combination; C 2-year OS rate in newly in newly diagnosed AML patients treated with IDH inhibitors alone; D 2-year OS rate in relapsed or refractory AML patients treated with IDH inhibitors alone; E Median OS in relapsed or refractory AML patients treated with IDH inhibitors alone. OS overall survival, AML acute myeloid leukemia, IDH isocitrate dehydrogenase genes, 95% CI 95% confidence interval

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us